Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphomaDanielle H. Oh(Peter MacCallum Cancer Centre), Jake Shortt(The University of Melbourne)Proceedings of the National Academy of SciencesAugust 29, 202310.1073/pnas.2306414120Cited by 9SaveCiteExport RISWatch citationsRelated PapersTargeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition|Molecular Cell|2021|167The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock|Oncogenesis|2016|32